Arvinas Inc.

New phase 1_2 trial NCT07023731 posted by Arvinas Inc.: "A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation". New trial on a phase 1_2 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 20 days ago.

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.